Some of the less investigated mechanisms to BCR::ABL1 TKI resistance are epigenetic changes such as HOXA4 promoter hypermethylation, which could lead to IM resistance in CML patients. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.